CANCER BIOLOGICS MARKET ANALYSIS(2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
CANCER BIOLOGICS MARKET ANALYSIS (2020-2027)

• Cancer Biologics Market, by Product (Monoclonal
  Antibodies, Cytokine-Based Immunotherapy, Cancer
  Vaccines, CAR-T Cell Therapy, and Immune
  Checkpoint Inhibitors), by Application (Non-small
  Cell Lung Cancer, Prostate Cancer, Breast Cancer,
  Acute Myeloid Leukemia, Lymphoma, Multiple
  Myeloma, Ovarian Cancer, Colorectal Cancer,
  Gastric Cancers, and Others), by Distribution
  Channel (Hospitals, Clinics, and Others), and by
  Region (North America, Latin America, Europe,
  Middle East, Asia Pacific, and Africa) - Size,
  Share, Outlook, and Opportunity Analysis, 2020 -
  2027

3

• Biologic drug is a product that contain
  components of living organisms such as animal,
  human, or produced from living organisms.
  Antibodies, vaccines, and interleukins are some
  examples of biologic drugs. Furthermore, biologic
  drugs are administrated by injection or infusion,
  as biologic products can easily lose their
  potency due to acid present in the stomach, if
  administered by oral route to the patient.
  Moreover, biologic drug for cancer treatment
  helps to increase the bodys ability to fight
  against various types of cancers such as
  nasopharyngeal cancer, prostate cancer, breast
  cancer, neck cancer, and lung cancer.
  Pembrolizumab, Atezolizumab, Cemiplimab-rwlc,
  Blinatumomab and Durvalumab are few examples of
  biologic drugs that are used for the treatment of
  cancer.

4
Global Cancer Biologics Market Drivers

• The global cancer biologics market is expected to
  witness significant growth over the forecast
  period, owing to increasing approvals of biologic
  drug by regulatory authorities for the treatment
  of cancer. For instance, in 2018, the U.S Food
  and Drug Administration (FDA) approved
  blinatumomab, for the patient suffering from
  B-cell precursor acute lymphoblastic leukemia,
  which show reduction in the severity of the
  disease, as the minimal residual disease (MRD) is
  found to be greater than or equal to 0.1.
  Furthermore, in 2018, U.S FDA approved
  Cemiplimab-rwlc, for the treatment metastatic
  advanced stage cutaneous squamous cell cancer.
  The recommended Cemiplimab-rwlc dose for the
  patient is 350 mg, which is administrated as
  intravenous infusion over 30 minutes, in every
  three weeks.

5

• Moreover, in January 2020, F. Hoffmann-La Roche
  AG announced about its submission of supplemental
  biological license to U.S Food and Drug
  Administration (FDA) for Tecentriq
  (atezolizumab), in combination with Avastin
  (bevacizumab) drug for most common form of liver
  cancer. Therefore, increasing number of
  regulatory approvals of biologic drug for the
  treatment of cancer, is expected to boost of
  cancer biologics market growth over the forecast
  period.

6

• Global Cancer Biologics Market Restraints
• However, high cost associated with cancer
  biologic drug is one of the major restraint that
  is expected to hamper the global cancer biologics
  market growth. For instance, cost of blinatumomab
  is US 17,800 per year. Furthermore, side effects
  associated with cancer biologic drug such as
  allergic reactions, injection site reactions,
  weakness, diarrhea, nausea, vomiting, and rash
  yet remains another factor hindering the global
  cancer biologics market growth.

7

• Global Cancer Biologics Market Regional Analysis
• North America is expected to account for highest
  market share in the global cancer biologics
  market, owing to increasing prevalence of cancer,
  among people in North America. For instance, in
  2019, in the U.S, according to the American
  Cancer Societys (ACS), around 1,762,450 new
  cancer cases were diagnosed, and 606,880 new
  cancer deaths were reported.
• Furthermore, increasing drug approvals for the
  treatment of metastatic merkel cell carcinoma
  (MCC) by the company is one of the factors that
  is driving the global cancer biologic market
  growth. For instance, in 2018, pembrolizumab recei
  ved approval from the U.S. Food and Drug
  Administration (FDA) for the treatment of
  patients suffering from metastatic Merkel cell
  carcinoma (MCC).

8

• Europe is expected to account for second highest
  market share in the global cancer biologics
  market, owing to increasing prevalence of cancer
  in Europe region. For instance, in 2018, around
  3.9 million of cancer with new cases excluding
  non-melanoma skin cancer, and 1.9 million death
  from cancer were reported by the International
  Agency for Research on Cancer (IARC), in
  collaboration with the European Network of Cancer
  Registries (ENCR, as well as the European
  Commissions Joint Research Centre (JRC).

9

• Moreover, Asia Pacific is expected to exhibit
  CAGR over the forecast period due to the
  increasing approval of drugs by regulatory bodies
  for the treatment of Hodgkin's disease (blood
  cancer) by the company. For instance, in 2018,
  National Medical Products Administration (NMPA)
  of China approved Sintilimab injection, which is
  sold under the brand name Tyvyt, and was jointly
  announced by Innovent Biologics, Inc. and Eli
  Lilly and Company. Sintilimab injection is used
  for the treatment of Hodgkin's disease (blood
  cancer), and is fully human IgG4 monoclonal
  antibody.

10

• Global Cancer Biologics Market Key Players
• Key players operating in the global cancer
  biologic market are Merck Co., Inc., Novartis
  International AG, F. Hoffmann-La Roche AG, Eli
  Lilly and Company, Bristol-Myers Squibb Company,
  Amgen Inc., Pfizer Inc., Sanofi S.A., Bayer AG,
  EnGeneIC Ltd, and GlaxoSmithKline PLC.

11

• Market Taxonomy
• On the basis of product, the global cancer
  biologics market is segmented into
• Monoclonal Antibodies
• Naked Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• Chemo labeled Antibodies
• Radiolabeled Antibodies
• Bispecific Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• Treatment Vaccines
• Preventive Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors
• CTL-4 Checkpoint Inhibitor
• PD-1 PD-L1 Checkpoint Inhibitor

12

• On the basis of application, the global cancer
  biologics market is segmented into
• Non-Small Cell Lung Cancer
• Prostate Cancer 
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Others

13

• On the basis of distribution channel, the global
  cancer biologics market is segmented into
• Hospital
• Clinic
• Others
• On the basis of region, the global cancer
  biologics market is segmented into
• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

14

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/o
  ngoing-insight/cancer-biologics-market-4145

15
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

16
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

17

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/